Join
Live feed
·
INSIDERFilingvia Quantisnow
Karyopharm Therapeutics Inc. logo

EVP, Chief Development Officer Poulton Stuart was granted 896 shares and sold $3,828 worth of shares (403 units at $9.50), increasing direct ownership by 0.52% to 94,821 units (SEC Form 4) (tax withholding)

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KPTI (Karyopharm Therapeutics Inc.) and more on Quantisnow.